Antibody-based drugs targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1) and programmed cell death protein-ligand 1 (PD-L1) have proven superior to existing chemotherapy and radiation approaches for multiple cancer types [109]. This evidence concerns the gene PDCD1 and cancer.